All Posts Tagged With: "TEVA"
(AZN) US Court Rejects AstraZeneca’s Case
Recently, AstraZeneca (AZN) announced that US District Court for the District of Columbia has dismissed the lawsuit filed by the company against the US Food and Drug Administration (FDA).
AstraZeneca...
(TEVA) Teva Pharmaceutical Industries Active on the Generics Front
Teva Pharmaceutical Industries Ltd. (TEVA) has been pretty active on the generic product launch front with the company launching several generic products in the last few weeks. Among recently launched generic...
(MYGN) Myriad Inks Deal with Cephalon
The recent agreement with Cephalon is another attempt by Myriad Genetics (MYGN) to establish itself as a strong player in the companion diagnostic market. Cephalon is a subsidiary of Teva Pharmaceuticals...
(FRX) Forest Laboratories and Janssen Pharmaceutica Sue Generic Players
Forest Laboratories, Inc. (FRX) and Janssen Pharmaceutica NV, a Johnson & Johnson (JNJ) company, recently filed a joint lawsuit against...
(PRGO) Perrigo Analyst Maintains Neutral Share rating
We have maintained our Neutral rating on Perrigo Company (PRGO) with a target price of $100.00 following appraisal of second quarter of fiscal 2012 results.
Perrigo reported second quarter EPS of $1.20,...
(SHPGY) Shire and Sangamo BioSciences Cut a Deal
Shire plc (SHPGY) and Sangamo BioSciences, Inc. (SGMO) recently entered into a collaboration and license agreement for the development...
(BMY) Company News for January 04, 2012 – Corporate Summary
• Share prices of natural gas producer Devon Energy Corp (NYSE:DVN) gained 6.63% after the company announced it would sell a stake in five of its exploratory projects across the U.S., to Sinopec International Petroleum...
(JNJ) Pharma & Biotech Stock Review & Outlook – Industry Outlook
With 2011 coming to an end, the pharmaceutical industry continues to face challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a...
(TEVA) Teva Pharmaceutical Industries Provides In-Line 2012 Outlook
Teva Pharmaceutical Industries Ltd. (TEVA) recently provided guidance for 2012. The company expects to earn $5.48 and $5.68 per share on total net sales of about $22 billion. Guidance was generally in line...
(PFE) Watson Pharmaceuticals Joins Pfizer for Generic Lipitor
November 30, 2011 was a big day for Pfizer, Inc. (PFE) with its blockbuster cholesterol drug, Lipitor, losing exclusivity in the US. With so many drugs losing exclusivity, why is the loss of exclusivity of...
(MYL) Mylan Earns FDA Approval
Generic maker, Mylan Inc. (MYL) recently announced that its Indian subsidiary Mylan Laboratories has received tentative approval from the US Food & Drug Administration (FDA) for a fixed-dose combination...
(MYL) Mylan Approved for Zinecard Generic
Mylan, Inc.’s (MYL) generic business was boosted further with the approval from the U.S. Food and Drug Administration (FDA) for its generic version of Pharmacia & Upjohn’s Zinecard injection. Zinecard...
(MYL) Mylan Settles with Novartis
Mylan, Inc. (MYL) recently announced a settlement agreement with Novartis (NVS) relating to the generic version of Novartis’ bioidentical...
(AEM) Company News for November 4, 2011 – Corporate Summary
• Allos Therapeutics (NASDAQ:ALTH) posted a Q3 loss of $0.11 per share, lower than the Zacks Consensus Estimate for a loss of $0.15 per share. Revenues for the quarter rose 73.2% year-over-year to $14.2 million, surpassing...
(PRGO) Perrigo Beats Earnings Forecast – Sales Miss
Perrigo Company (PRGO) reported earnings per share of $1.10 for the first quarter of fiscal 2012, beating the Zacks Consensus Estimate of $1.03 and the year-earlier earnings of 87 cents per share. Light sales...
(MYL) Mylan Settles with Roche for Xeloda
Mylan Inc. (MYL) recently announced that it has entered into a settlement and license agreement with Roche (RHHBY) bringing an end to its ongoing litigation with the latter relating to Roche’s...
(EU) Pharmaceuticals Stock Outlook – September 2011 – Industry Outlook
The pharmaceutical industry continues to be impacted by major issues such as sluggish prescription trends, European Union (EU) pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to witness a significant imbalance...
(TEVA) Teva Pharmaceutical Industries Earns Favorable Court Ruling
Teva Pharmaceutical Industries Ltd. (TEVA) recently received a boost with the US District Court for the Southern District of New York issuing a favorable ruling related to the company’s patent infringement...
(MYL) Mylan Analyst Reaffirms Shares at Neutral
We have maintained our Neutral recommendation on Mylan Inc. (MYL) with a target price of $19.00 following an appraisal of second quarter 2011 financial results.
Mylan’s second quarter 2011 earnings...
(MYL) Mylan and Endo Pharmaceuticals in Legal Tussle
Mylan Inc. (MYL) recently announced that Endo Pharmaceuticals (ENDP) filed a patent infringement lawsuit in connection with an abbreviated...
(MYL) Mylan Beats Second Quarter Earnings on All Fronts
Mylan Inc.’s (MYL) second quarter 2011 earnings (excluding special items) of 52 cents per share were above the Zacks Consensus Estimate of 45 cents as well as the year-ago earnings of 37 cents per share....
(BHP) Company News for July 18, 2011 – Corporate Summary
• BHP Billiton Ltd. (NYSE:BHP) said it will be acquiring Petrohawk Energy Corporation (NYSE:HK) for $12.1 billion
• Investor Carl Icahn offered to buy...
(MYL) Mylan Gets HIV Rights from Gilead
Mylan, Inc. (MYL) recently announced that its Indian subsidiary Matrix Laboratories has been granted future rights to produce and sell generic versions of three investigational HIV therapies of Gilead...
(PRGO) Perrigo Downgraded to Neutral
We recently moved to a Neutral rating on Perrigo Company (PRGO) from Outperform. Our target price on the stock is $94.00.
Perrigo’s broad line of store brand pharmaceutical products has the same...
(MS) Merck KGaA Seeks Rebif Extension
Merck KGaA (MKGAF) recently filed a marketing application with the European Medicines Agency (EMA) in its endeavor to expand the label of Rebif, its multiple sclerosis (MS) therapy. The company is seeking...
(MS) Merck KGaA to Withdraw Multiple Sclerosis Drug
Merck KGaA (MKGAF) recently announced its plans to withdraw the regulatory applications filed with the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), seeking approval to market...
(MYL) Trial Date for Teva Pharmaceuticals / Mylan Dispute
Mylan Inc. (MYL) received some good news recently when a US District court denied Teva Pharmaceuticals Industries’ (TEVA) motion for a...
(WPI) Watson Pharmaceuticals Wins Favorable Ruling Against Teva Pharmaceutical Industries
Watson Pharmaceuticals Inc. (WPI) recently announced that the United States District Court for the District of Nevada denied Teva Pharmaceutical Industries Ltd.’s (
21Jun2011 | vitalstocks | 0 comments | Continued(JNJ) Pharma & Biotech Stock Outlook – June 2011 – Industry Outlook
Challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts continue to impact the pharmaceutical industry. The next five years are expected to reflect a significant imbalance between...
(MDCO) The Medicines Company Analyst Reiterates Neutral on Shares
We recently reiterated a Neutral recommendation on The Medicines Company (MDCO), which carries a Zacks #3 Rank (short-term Hold rating). The Medicines Company reported a first-quarter profit of 60 cents per...